One-year transplant-free survival following hospital discharge after ICU Admission for ACLF in the Netherlands.
Acute-on-chronic liver failure
critical care
liver cirrhosis
liver transplantation
organ failure
risk factors, mortality
survivors
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
12
07
2023
revised:
05
03
2024
accepted:
06
03
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Patients with acute decompensated (AD) liver cirrhosis or acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. Existing research, mostly from specialized liver transplant centers, largely addresses short-term outcomes. Our aim was to evaluate in-hospital mortality and 1-year transplant-free survival after hospital discharge in the Netherlands. We conducted a nationwide observational cohort study, including patients with an history of cirrhosis or first complications of cirrhotic portal hypertension admitted to ICUs in the Netherlands between 2012 and 2020. The influence of ACLF grade at ICU admission on 1-year transplant-free survival after hospital discharge among hospital survivors was evaluated using unadjusted Kaplan-Meier (KM) survival curve and adjusted Cox proportional hazard model. Out of the 3,035 patients, 1,819 (59.9%) had ACLF grade 3. 1420 patients (46.8%) survived hospitalization after ICU admission. The overall probability of 1-year transplant-free survival after hospital discharge was 0.61 (95% CI 0.59-0.64). This rate varied with ACLF grade at ICU admission, being highest in patients without ACLF (0.71 [95% CI 0.66-0.76]) and lowest in those with ACLF-3 (0.53 [95% CI 0.49-0.58]) (Logrank P < 0.0001). However, after adjusting for age, malignancy status and MELD-score, ACLF grade at ICU admission was not associated with an increased risk of liver transplantation or death within one year after hospital discharge. In this nationwide cohort study, ACLF grade at ICU admission did not independently affect 1-year transplant-free survival after hospital discharge. Instead, age, presence of malignancy and the severity of liver disease played a more prominent role in influencing transplant-free survival after hospital discharge. Patients with Acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. In these patients' short-term mortality is high, but long-term outcomes of survivors remain unknown. Using a large nationwide cohort of ICU patients, we discovered that the severity of ACLF at ICU admission does not influence one-year transplant-free survival after hospital discharge. Instead, age, malignancy status and overall severity of liver disease are more critical factors in determining their long-term survival.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Patients with acute decompensated (AD) liver cirrhosis or acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. Existing research, mostly from specialized liver transplant centers, largely addresses short-term outcomes. Our aim was to evaluate in-hospital mortality and 1-year transplant-free survival after hospital discharge in the Netherlands.
METHODS
METHODS
We conducted a nationwide observational cohort study, including patients with an history of cirrhosis or first complications of cirrhotic portal hypertension admitted to ICUs in the Netherlands between 2012 and 2020. The influence of ACLF grade at ICU admission on 1-year transplant-free survival after hospital discharge among hospital survivors was evaluated using unadjusted Kaplan-Meier (KM) survival curve and adjusted Cox proportional hazard model.
RESULTS
RESULTS
Out of the 3,035 patients, 1,819 (59.9%) had ACLF grade 3. 1420 patients (46.8%) survived hospitalization after ICU admission. The overall probability of 1-year transplant-free survival after hospital discharge was 0.61 (95% CI 0.59-0.64). This rate varied with ACLF grade at ICU admission, being highest in patients without ACLF (0.71 [95% CI 0.66-0.76]) and lowest in those with ACLF-3 (0.53 [95% CI 0.49-0.58]) (Logrank P < 0.0001). However, after adjusting for age, malignancy status and MELD-score, ACLF grade at ICU admission was not associated with an increased risk of liver transplantation or death within one year after hospital discharge.
CONCLUSION
CONCLUSIONS
In this nationwide cohort study, ACLF grade at ICU admission did not independently affect 1-year transplant-free survival after hospital discharge. Instead, age, presence of malignancy and the severity of liver disease played a more prominent role in influencing transplant-free survival after hospital discharge.
IMPACT AND IMPLICATIONS
UNASSIGNED
Patients with Acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. In these patients' short-term mortality is high, but long-term outcomes of survivors remain unknown. Using a large nationwide cohort of ICU patients, we discovered that the severity of ACLF at ICU admission does not influence one-year transplant-free survival after hospital discharge. Instead, age, malignancy status and overall severity of liver disease are more critical factors in determining their long-term survival.
Identifiants
pubmed: 38479613
pii: S0168-8278(24)00155-7
doi: 10.1016/j.jhep.2024.03.004
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest NK reports a relationship with Netherlands Ministry of Health Welfare and Sport that includes consulting or advisory. CH reports relationships with: Takeda Pharmaceutical Company that includes consulting or advisory; Abacus Medicine that includes speaking and lecture fees; Orphalan Limited that includes speaking and lecture fees; Novartis that includes speaking and lecture fees; and the Foundation for Liver and Gastrointestinal Research that includes board membership. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.